Remarkably, such an anti-proliferative effect was significantly enhanced by ERA since the proliferation reduction reached 92% and 95% at 72 h in combined treatments, suggesting that SLC7A11 antiporter activity is necessary for cancer survival under HBP inhibition. Here, SLC7A11 is linked to cancer.